{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:28:41Z","timestamp":1790735321470,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["14\/0004472"],"award-info":[{"award-number":["14\/0004472"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KMG","award":["14\/0004869"],"award-info":[{"award-number":["14\/0004869"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Zinc transporter 8 autoantibodies (ZnT8A) are thought to appear close to type 1 diabetes (T1D) onset and can identify high-risk multiple (\u22652) autoantibody positive individuals. Radiobinding assays (RBA) are widely used for ZnT8A measurement but have limited sustainability. We sought to develop a novel, high-performance, non-radioactive luciferase immunoprecipitation system (LIPS) assay to replace RBA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A custom dual C-terminal ZnT8 (aa268-369; R325\/W325) heterodimeric antigen, tagged with a NanoluciferaseTM (Nluc-ZnT8) reporter, and LIPS assay was developed. Assay performance was evaluated by testing sera from new onset T1D (n\u2005=\u2005573), healthy schoolchildren (n\u2005=\u2005521), and selected first-degree relatives (FDRs) from the Bart\u2019s Oxford family study (n\u2005=\u2005617; 164 progressed to diabetes).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In new-onset T1D, ZnT8A levels by LIPS strongly correlated with RBA (Spearman\u2019s r\u2005=\u20050.89; P\u2005&amp;lt;\u20050.0001), and positivity was highly concordant (94.3%). At a high specificity (95%), LIPS and RBA had comparable assay performance [LIPS pROC-AUC(95) 0.032 (95% CI: 0.029\u20130.036); RBA pROC-AUC(95) 0.031 (95% CI: 0.028\u20130.034); P\u2005=\u20050.376]. Overall, FDRs found positive by LIPS or RBA had a comparable 20-year diabetes risk (52.6% and 59.7%, respectively), but LIPS positivity further stratified T1D risk in FDRs positive for at least one other islet autoantibody detected by RBA (P\u2005=\u20050.0346).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This novel, high-performance, cheaper, quicker, higher throughput, low blood volume Nluc-ZnT8 LIPS assay is a safe, non-radioactive alternative to RBA with enhanced sensitivity and ability to discriminate T1D progressors. This method offers an advanced approach to current strategies to screen the general population for T1D risk for immunotherapy trials and to reduce rates of diabetic ketoacidosis at diagnosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cei\/uxad139","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T16:18:13Z","timestamp":1703434693000},"page":"215-224","source":"Crossref","is-referenced-by-count":18,"title":["A novel, high-performance, low-volume, rapid luciferase immunoprecipitation system (LIPS) assay to detect autoantibodies to zinc transporter 8"],"prefix":"10.1093","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-8018","authenticated-orcid":false,"given":"Claire L","family":"Williams","sequence":"first","affiliation":[{"name":"Translational Health Sciences, Bristol Medical School, University of Bristol , Southmead Hospital, Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4765-4509","authenticated-orcid":false,"given":"Ilaria","family":"Marzinotto","sequence":"additional","affiliation":[{"name":"San Raffaele Diabetes Research Institute, IRCCS San Raffaele Scientific Institute , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Brigatti","sequence":"additional","affiliation":[{"name":"San Raffaele Diabetes Research Institute, IRCCS San Raffaele Scientific Institute , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3009-8032","authenticated-orcid":false,"given":"Kathleen M","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Translational Health Sciences, Bristol Medical School, University of Bristol , Southmead Hospital, Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The BOX Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Megson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitrabhanu","family":"Ballav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanu","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Russell-Taylor","sequence":"additional","affiliation":[{"name":"Bucks Healthcare Trust , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Besser","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals Trust UK , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bursell","sequence":"additional","affiliation":[{"name":"University Hospital , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthi","family":"Chandran","sequence":"additional","affiliation":[{"name":"University Hospital , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Keynes","sequence":"additional","affiliation":[{"name":"University Hospital , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejal","family":"Patel","sequence":"additional","affiliation":[{"name":"Wexham Park Hospital , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Smith","sequence":"additional","affiliation":[{"name":"Northampton General Hospital , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manohara","family":"Kenchaiah","sequence":"additional","affiliation":[{"name":"Northampton General Hospital , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gomathi","family":"Margabanthu","sequence":"additional","affiliation":[{"name":"Kettering General Hospital , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Kavvoura","sequence":"additional","affiliation":[{"name":"Royal Berkshire Hospital , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Yaliwal","sequence":"additional","affiliation":[{"name":"Royal Berkshire Hospital , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Lampasona","sequence":"additional","affiliation":[{"name":"San Raffaele Diabetes Research Institute, IRCCS San Raffaele Scientific Institute , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair J K","family":"Williams","sequence":"additional","affiliation":[{"name":"Translational Health Sciences, Bristol Medical School, University of Bristol , Southmead Hospital, Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6847-2771","authenticated-orcid":false,"given":"Anna E","family":"Long","sequence":"additional","affiliation":[{"name":"Translational Health Sciences, Bristol Medical School, University of Bristol , Southmead Hospital, Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"2024022515060478300_CIT0001","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.2337\/dc10-2268","article-title":"Contribution of antibodies against IA-2beta and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age","volume":"34","author":"Vermeulen","year":"2011","journal-title":"Diabetes Care"},{"key":"2024022515060478300_CIT0002","doi-asserted-by":"crossref","first-page":"e14979","DOI":"10.1111\/dme.14979","article-title":"The measurement of autoantibodies to insulin informs diagnosis of diabetes in a childhood population negative for other autoantibodies","volume":"39","author":"Williams","year":"2022","journal-title":"Diabet Med"},{"key":"2024022515060478300_CIT0003","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2013.6285","article-title":"Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children","volume":"309","author":"Ziegler","year":"2013","journal-title":"JAMA"},{"key":"2024022515060478300_CIT0004","first-page":"4264","article-title":"Antiislet autoantibodies usually develop sequentially rather than simultaneously","volume":"81","author":"Yu","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2024022515060478300_CIT0005","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2337\/dc16-2228","article-title":"Twenty-year progression rate to clinical onset according to autoantibody profile, age, and HLA-DQ genotype in a registry-based group of children and adults with a first-degree relative with type 1 diabetes","volume":"40","author":"Gorus","year":"2017","journal-title":"Diabetes Care"},{"key":"2024022515060478300_CIT0006","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/diabetes.53.2.384","article-title":"Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics","volume":"53","author":"Achenbach","year":"2004","journal-title":"Diabetes"},{"key":"2024022515060478300_CIT0007","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.2337\/dc19-2547","article-title":"Hierarchical order of distinct autoantibody spreading and progression to type 1 diabetes in the TEDDY study","volume":"43","author":"Vehik","year":"2020","journal-title":"Diabetes Care"},{"key":"2024022515060478300_CIT0008","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2337\/dc17-0806","article-title":"Type 1 diabetes TrialNet: a multifaceted approach to bringing disease-modifying therapy to clinical use in type 1 diabetes","volume":"41","author":"Bingley","year":"2018","journal-title":"Diabetes Care"},{"key":"2024022515060478300_CIT0009","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1007\/s00125-018-4591-5","article-title":"Characteristics of slow progression to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL study","volume":"61","author":"Long","year":"2018","journal-title":"Diabetologia"},{"key":"2024022515060478300_CIT0010","doi-asserted-by":"crossref","first-page":"17040","DOI":"10.1073\/pnas.0705894104","article-title":"The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes","volume":"104","author":"Wenzlau","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024022515060478300_CIT0011","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00125-009-1438-0","article-title":"Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk","volume":"52","author":"Achenbach","year":"2009","journal-title":"Diabetologia"},{"key":"2024022515060478300_CIT0012","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00125-012-2472-x","article-title":"Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes","volume":"55","author":"Ziegler","year":"2012","journal-title":"Diabetologia"},{"key":"2024022515060478300_CIT0013","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00125-009-1618-y","article-title":"Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials","volume":"53","author":"De Grijse","year":"2010","journal-title":"Diabetologia"},{"key":"2024022515060478300_CIT0014","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2337\/dc11-2081","article-title":"Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies","volume":"35","author":"Yu","year":"2012","journal-title":"Diabetes Care"},{"key":"2024022515060478300_CIT0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2249.2012.04675.x","article-title":"Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients","volume":"171","author":"Gorus","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"2024022515060478300_CIT0016","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.2337\/db08-0522","article-title":"A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes","volume":"57","author":"Wenzlau","year":"2008","journal-title":"Diabetes"},{"key":"2024022515060478300_CIT0017","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s001250051044","article-title":"Familial risk of type I diabetes in European children The Eurodiab Ace Study Group and The Eurodiab Ace Substudy 2 Study Group","volume":"41","author":"The Eurodiab Ace Study Group","year":"1998","journal-title":"Diabetologia"},{"key":"2024022515060478300_CIT0018","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00592-017-1082-y","article-title":"A novel LIPS assay for insulin autoantibodies","volume":"55","author":"Liberati","year":"2018","journal-title":"Acta Diabetol"},{"key":"2024022515060478300_CIT0019","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1021\/cb3002478","article-title":"Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate","volume":"7","author":"Hall","year":"2012","journal-title":"ACS Chem Biol"},{"key":"2024022515060478300_CIT0020","doi-asserted-by":"crossref","first-page":"e14717","DOI":"10.1111\/dme.14717","article-title":"Four decades of the Bart\u2019s Oxford study: Improved tests to predict type 1 diabetes","volume":"38","author":"Gillespie","year":"2021","journal-title":"Diabet Med"},{"key":"2024022515060478300_CIT0021","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00125-006-0160-4","article-title":"Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk","volume":"49","author":"Bingley","year":"2006","journal-title":"Diabetologia"},{"key":"2024022515060478300_CIT0022","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2337\/diab.46.11.1701","article-title":"Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers","volume":"46","author":"Bingley","year":"1997","journal-title":"Diabetes"},{"key":"2024022515060478300_CIT0023","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1210\/jc.2010-0293","article-title":"Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for National Institute of Diabetes and digestive and kidney diseases consortia","volume":"95","author":"Bonifacio","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2024022515060478300_CIT0024","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1006\/jaut.1997.0154","article-title":"A novel micro-assay for insulin autoantibodies","volume":"10","author":"Williams","year":"1997","journal-title":"J Autoimmun"},{"key":"2024022515060478300_CIT0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2337\/diacare.16.1.45","article-title":"Can islet cell antibodies predict IDDM in the general population","volume":"16","author":"Bingley","year":"1993","journal-title":"Diabetes Care"},{"key":"2024022515060478300_CIT0026","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/db11-0962","article-title":"Rising incidence of type 1 diabetes is associated with altered immunophenotype at diagnosis","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"key":"2024022515060478300_CIT0027","article-title":"Improved specificity of glutamate decarboxylase 65 autoantibody measurement using luciferase-based immunoprecipitation system (LIPS) assays","author":"Wyatt","year":"2023","journal-title":"medRxiv"},{"key":"2024022515060478300_CIT0028","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinf"},{"key":"2024022515060478300_CIT0029","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/dmrr.1268","article-title":"LIPS islet autoantibody assays in high-throughput format for DASP 2010","volume":"27","author":"Marcus","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"2024022515060478300_CIT0030","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.2337\/dc08-0286","article-title":"A new luminescence assay for autoantibodies to mammalian cell-prepared insulinoma-associated protein 2","volume":"31","author":"Burbelo","year":"2008","journal-title":"Diabetes Care"},{"key":"2024022515060478300_CIT0031","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jim.2014.01.009","article-title":"Development of a luciferase-based system for the detection of ZnT8 autoantibodies","volume":"405","author":"Ustinova","year":"2014","journal-title":"J Immunol Methods"},{"key":"2024022515060478300_CIT0032","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.2337\/db15-1058","article-title":"Identification of tetraspanin-7 as a target of autoantibodies in type 1 diabetes","volume":"65","author":"McLaughlin","year":"2016","journal-title":"Diabetes"},{"key":"2024022515060478300_CIT0033","doi-asserted-by":"crossref","first-page":"e002296","DOI":"10.1136\/bmjdrc-2021-002296","article-title":"Zinc transporter 8 autoantibody testing requires age-related cut-offs","volume":"9","author":"Grace","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2024022515060478300_CIT0034","doi-asserted-by":"crossref","first-page":"102677","DOI":"10.1016\/j.jaut.2021.102677","article-title":"Novel autoantibodies to the beta-cell surface epitopes of ZnT8 in patients progressing to type-1 diabetes","volume":"122","author":"Gu","year":"2021","journal-title":"J Autoimmun"},{"key":"2024022515060478300_CIT0035","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/jama.2019.21565","article-title":"Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany","volume":"323","author":"Ziegler","year":"2020","journal-title":"JAMA"},{"key":"2024022515060478300_CIT0036","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.2337\/dc19-0593","article-title":"Who is enrolling? The path to monitoring in type 1 diabetes TrialNet\u2019s pathway to prevention","volume":"42","author":"Sims","year":"2019","journal-title":"Diabetes Care"},{"key":"2024022515060478300_CIT0037","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cca.2015.05.010","article-title":"Bridging-type enzyme-linked immunoassay for zinc transporter 8 autoantibody measurements in adult patients with diabetes mellitus","volume":"447","author":"Dunseath","year":"2015","journal-title":"Clin Chim Acta"},{"key":"2024022515060478300_CIT0038","first-page":"3455","article-title":"High-affinity ZnT8 autoantibodies by electrochemiluminescence assay improve risk prediction for type 1 diabetes","volume":"106","author":"Jia","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2024022515060478300_CIT0039","doi-asserted-by":"crossref","first-page":"10196","DOI":"10.1073\/pnas.1711169114","article-title":"Proteoliposome-based full-length ZnT8 self-antigen for type 1 diabetes diagnosis on a plasmonic platform","volume":"114","author":"Wan","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024022515060478300_CIT0040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cca.2016.08.013","article-title":"3 Screen islet cell autoantibody ELISA: a sensitive and specific ELISA for the combined measurement of autoantibodies to GAD65, to IA-2 and to ZnT8","volume":"462","author":"Amoroso","year":"2016","journal-title":"Clin Chim Acta"},{"key":"2024022515060478300_CIT0041","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1089\/dia.2021.0517","article-title":"High-throughput multiplex electrochemiluminescence assay applicable to general population screening for type 1 diabetes and celiac disease","volume":"24","author":"He","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2024022515060478300_CIT0042","doi-asserted-by":"crossref","first-page":"113265","DOI":"10.1016\/j.jim.2022.113265","article-title":"Multiplex agglutination-PCR (ADAP) autoantibody assays compared to radiobinding autoantibodies in type 1 diabetes and celiac disease","volume":"506","author":"Lind","year":"2022","journal-title":"J Immunol Methods"},{"key":"2024022515060478300_CIT0043","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"2024022515060478300_CIT0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci Transl Med"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxad139\/56334085\/uxad139.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/215\/3\/215\/56754974\/uxad139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/215\/3\/215\/56754974\/uxad139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T15:06:38Z","timestamp":1708873598000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/215\/3\/215\/7502706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,12,27]]},"published-print":{"date-parts":[[2024,2,19]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxad139","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,12,27]]}}}